KCT0007901Not yet recruiting未知
A Study of Treatment-free remission Evaluation in Real-world chronic myeloid leukemia-Prospective observational study
Trial Snapshot
- Phase
- 未知
- Status
- Not yet recruiting
- Enrollment
- 200
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational Study
Eligibility Criteria
- Ages
- 19(Year) to o Limit (—)
- Sex
- All
Inclusion Criteria
- •1.> 18-year-old male or female patient
- •2. ECOG execution status 0, 1 or 2
- •3. Patients diagnosed with BCR/ABL positive chronic-phaseCML by bone marrow examination
- •4. Patients receiving TKI treatment for at least three years after initial diagnosis, including imatinib, dasatinib, nilotinib, radotinib, etc.
- •5. For qRT-PCR follow-up observation, patients with BCR/ABL1RQ-PCR < 0.0069IS (MR4.3 or higher) maintained for more than 2 years and had another confirmed response of 0.0069IS or less at the central genetic testing institution that contracted for analysis.
- •6. Patients who agreed to participate in the study
Exclusion Criteria
- •1. Patients who had previously performed allografts
- •2. Patients who tried to interrupt TKI before
- •3. Past history of other active malignancies within 5 years prior to participation in clinical research, excluding fully cured or present basal cell skin cancer and past cervical endothelial cancer
- •4. Patients who have not recovered from previous surgery
- •5. Patients treated with other clinical research preparations within one to four weeks prior to the time of registration of the study
- •6. Pregnant or lactating women
- •7. Patients who may pose a risk to patient safety when determined by researchers
- •8. Patients who attempted TKI interruption for reasons other than TFR
Investigators
Similar Trials
Terminated
Phase 2
A programme of development for older patients with acute myeloid leukaemia and high risk myelodysplastic syndromeAcute myeloid leukaemia (AML)Cancer - Leukaemia - Acute leukaemiaBlood - Haematological diseasesmyelodysplastic syndromeACTRN12612000848808Australasian Leukaemia and Lymphoma Group60
Completed
Phase 4
Evaluation of the clinical remission and its sustainment after discontinuation of infliximab in patients with rheumatoid arthritis who receive "programmed" treatment in randomized controlled trialRheumatoid ArthritisJPRN-UMIN000005113niversity of Occupational and Environmental Health, Japan450
Not yet recruiting
Not Applicable
Treatment free remission with generic ImatinibCTRI/2018/08/015357PGIMER CHANDIGARH
Completed
Not Applicable
Examination of the remission maintenance effect by low dose etanercept after clinical remission in the rheumatoid arthritis.Rheumatoid ArthritisJPRN-UMIN000013362Takarazuka city hospital60
Active, not recruiting
Not Applicable
A 3-Phase Study to Evaluate Sustained Remission and Productivity Outcomes in Subjects With Early Rheumatoid Arthritis Initiated on Treatment With Etanercept Plus Methotrexate - PRIZEModerate to severe early Rheumatoid Arthritis (RA).MedDRA version: 12.0Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2008-002623-85-ITWyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development300